Corcept Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 352

Employees

  • Stock Symbol
  • CORT

Stock Symbol

  • Share Price
  • $28.09
  • (As of Friday Closing)

Corcept Therapeutics General Information

Description

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Contact Information

Website
www.corcept.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 149 Commonwealth Drive
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corcept Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$28.09 $27.54 $20.84 - $34.27 $2.92B 104M 1.07M $1.15

Corcept Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 2,239,533 2,993,082 1,791,814 1,925,663
Revenue 523,529 482,375 401,858 365,978
EBITDA 123,611 109,644 116,080 127,953
Net Income 118,023 106,140 101,418 112,512
Total Assets 655,935 621,517 583,430 423,756
Total Debt 76 151 1,143 526
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corcept Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Corcept Therapeutics‘s full profile, request access.

Request a free trial

Corcept Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medica
Pharmaceuticals
Menlo Park, CA
352 As of 2023
00000
00000000000 00000

000000

tion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000000000000
Pasadena, CA
000 As of 0000
00.000
00000000 00.000

000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur
000000000000000
South San Francisco, CA
000 As of 0000
00000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Corcept Therapeutics Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA 000 00.000 00000000 00.000
Cytokinetics Formerly VC-backed South San Francisco, CA 000 00000 000000&0
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
BioMarin Pharmaceutical Formerly PE-Backed San Rafael, CA 0000 00000 0000 00000
You’re viewing 5 of 33 competitors. Get the full list »

Corcept Therapeutics Patents

Corcept Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240131020-A1 Formulations of glucocorticoid receptor modulators Pending 06-Oct-2022 00000000000
US-20240091218-A1 Methods of treating prostate cancer using exicorilant and enzalutamide Pending 02-Sep-2022 00000000000
US-20240091385-A1 Methods of assessing selective glucocorticoid receptor modulation and of identifying and treating patients likely to benefit from glucocorticoid receptor modulation Pending 02-Sep-2022 00000000000
US-20230416250-A1 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Pending 28-Jun-2022 0000000000
US-20230372312-A1 Methods of treating cushing's syndrome and liver disorders, and of reducing liver toxicity of other drugs administered to a patient Pending 20-May-2022 A61K31/437 0
To view Corcept Therapeutics’s complete patent history, request access »

Corcept Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
Joseph Belanoff MD Chief Executive Officer & Founder
Charles Robb JD Chief Business Officer
Hazel Hunt Ph.D Chief Scientific Officer
Sean Maduck Chief Commercial Officer
Atabak Mokari Chief Financial Officer, Finance
You’re viewing 5 of 12 executive team members. Get the full list »

Corcept Therapeutics Board Members (12)

Name Representing Role Since
Daniel Swisher Jr. Self Board Member 000 0000
David Mahoney Self Board Member 000 0000
George Baker Jr. Corcept Therapeutics Board Member 000 0000
Gillian Cannon Ph.D Self Board Member 000 0000
Gregg Alton JD Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Corcept Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Corcept Therapeutics ESG

Risk Overview

Risk Rating

Updated March, 22, 2024

27.66 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 456

Rank

00.00

Percentile

To view Corcept Therapeutics’s complete esg history, request access »

Corcept Therapeutics FAQs

  • When was Corcept Therapeutics founded?

    Corcept Therapeutics was founded in 1998.

  • Who is the founder of Corcept Therapeutics?

    Joseph Belanoff MD is the founder of Corcept Therapeutics.

  • Who is the CEO of Corcept Therapeutics?

    Joseph Belanoff MD is the CEO of Corcept Therapeutics.

  • Where is Corcept Therapeutics headquartered?

    Corcept Therapeutics is headquartered in Menlo Park, CA.

  • What is the size of Corcept Therapeutics?

    Corcept Therapeutics has 352 total employees.

  • What industry is Corcept Therapeutics in?

    Corcept Therapeutics’s primary industry is Pharmaceuticals.

  • Is Corcept Therapeutics a private or public company?

    Corcept Therapeutics is a Public company.

  • What is Corcept Therapeutics’s stock symbol?

    The ticker symbol for Corcept Therapeutics is CORT.

  • What is the current stock price of Corcept Therapeutics?

    As of 17-May-2024 the stock price of Corcept Therapeutics is $28.09.

  • What is the current market cap of Corcept Therapeutics?

    The current market capitalization of Corcept Therapeutics is $2.92B.

  • What is Corcept Therapeutics’s current revenue?

    The trailing twelve month revenue for Corcept Therapeutics is $524M.

  • Who are Corcept Therapeutics’s competitors?

    Arrowhead Pharmaceuticals, Cytokinetics, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and BioMarin Pharmaceutical are some of the 33 competitors of Corcept Therapeutics.

  • What is Corcept Therapeutics’s annual earnings per share (EPS)?

    Corcept Therapeutics’s EPS for 12 months was $1.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »